民生无小事丨惩治“阴阳价”！定点药店岂能“看人下菜碟”

Core Points - The article highlights the issue of "yin-yang pricing" in designated pharmacies, where the same cold medicine is priced at 17 yuan for non-insured individuals and 31 yuan for insured individuals, indicating a significant price discrepancy that undermines public trust in the healthcare system [1] - The behavior of pharmacies engaging in "yin-yang pricing" is attributed to their attempts to alleviate operational pressures by shifting costs onto insured patients, alongside a lack of transparency in drug pricing [1] - A recent notification has been issued to strengthen monitoring and handling of "yin-yang pricing" in designated retail pharmacies, emphasizing the need for strict investigations and penalties [1] Summary by Sections Section 1: Current Situation - Designated pharmacies are practicing "yin-yang pricing," which harms the security of medical insurance funds and the interests of insured individuals [1] - The price difference between insured and non-insured individuals for the same medication is nearly 100%, leading to public dissatisfaction and distrust [1] Section 2: Regulatory Response - A new notification has been released to address the issue, mandating serious investigations and actions against pharmacies engaging in "yin-yang pricing" [1] - Measures such as interviews, suspension of medical insurance settlements, and termination of service agreements may be implemented based on the severity of the violations [1] Section 3: Future Measures - Emphasis on the need for technological solutions, such as drug price comparison apps and traceability codes, to create a comprehensive supervision network [2] - Public reporting channels should be prominently displayed in pharmacies to enhance community oversight [2] - The article stresses that the qualification for medical insurance designated pharmacies should be viewed as a responsibility for honest business practices, not as a license for unregulated operations [2]